Bei Gene, Ltd. BGNE
We take great care to ensure that the data presented and summarized in this overview for BeiGene, Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BGNE
View all-
Baker Bros. Advisors LP New York, NY10.6MShares$1.83 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.22 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$895 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$865 Million0.59% of portfolio
-
Baillie Gifford & CO3.73MShares$645 Million0.46% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U03.01MShares$521 Million2.61% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.03MShares$350 Million0.04% of portfolio
-
Black Rock Inc. New York, NY949KShares$164 Million0.0% of portfolio
-
Capital International, Inc. Los Angeles, CA858KShares$148 Million1.89% of portfolio
-
Boxer Capital, LLC San Diego, CA500KShares$86.4 Million4.07% of portfolio
Latest Institutional Activity in BGNE
Top Purchases
Top Sells
About BGNE
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BGNE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 11
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
12,084
-67.24%
|
$1,764,264
$146.88 P/Share
|
Apr 10
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,716
-23.46%
|
$3,980,684
$149.55 P/Share
|
Apr 09
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
11,200
-7.86%
|
$1,713,600
$153.32 P/Share
|
Mar 13
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,332
-54.32%
|
$2,207,428
$179.91 P/Share
|
Mar 12
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
37,668
-19.26%
|
$6,215,220
$165.33 P/Share
|
Mar 11
2024
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
82,020
-2.95%
|
-
|
Feb 29
2024
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
397
-100.0%
|
$66,299
$167.08 P/Share
|
Nov 30
2023
|
Xiaodong Wang Director |
SELL
Other acquisition or disposition
|
Indirect |
172,372
-100.0%
|
-
|
Nov 30
2023
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
71,890
-1.3%
|
-
|
Nov 14
2023
|
Baker Bros. Advisors LP Director |
SELL
Open market or private sale
|
Indirect |
1,100,000
-9.43%
|
$198,000,000
$180.5 P/Share
|
Jul 31
2023
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
791
-100.0%
|
$170,856
$216.26 P/Share
|
Jul 03
2023
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
472
-100.0%
|
$84,488
$179.55 P/Share
|
Jun 26
2023
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
1,495
-100.0%
|
$272,090
$182.37 P/Share
|
Jun 26
2023
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,108
-99.77%
|
$201,656
$182.53 P/Share
|
Jun 23
2023
|
Corazon (Corsee) D. Sanders Director |
SELL
Open market or private sale
|
Direct |
578
-58.65%
|
$104,618
$181.7 P/Share
|
Jun 23
2023
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
840
-100.0%
|
$152,880
$182.85 P/Share
|
Jun 20
2023
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
1,753
-100.0%
|
$336,576
$192.44 P/Share
|
Jun 20
2023
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
190
-100.0%
|
$36,480
$192.54 P/Share
|
Jun 20
2023
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,325
-100.0%
|
$254,400
$192.42 P/Share
|
Jun 15
2023
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
355,641
+15.28%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.09M shares |
---|
Open market or private sale | 5.37M shares |
---|---|
Bona fide gift | 154K shares |
Other acquisition or disposition | 172K shares |